Mycophenolate mofetil for maintenance therapy in kidney transplantation

Clinical Transplantation

Volumn 10, Issue 1 II, 1996, Pages 128-130

  Gonwa, Thomas A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Kidney transplantation; Mycophenolate mofetil; Rejection

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

BLOOD DISEASE; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; VOMITING;

ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CYTOMEGALOVIRUS INFECTIONS; DIARRHEA; DOUBLE-BLIND METHOD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; NAUSEA; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PLACEBOS; PURINES; SAFETY; STEROIDS; VOMITING;

EID: 0029919822     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. NAIMARK DMJ, COLE E. Determinants of long-term renal graft survival. Transplant Rev 1994: 8: 93
2. BASADONNA GP, MATAS AJ, GILLINGHAM KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993: 55: 993.
3. CECKA JM. Early rejection: determining the fate of renal transplants. Transplant Proc 1991: 23(1 Part 2). 1263.
4. LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K. NELSON PH. Bioavailability improvement of mycophenolic acid through amino ester derivation. Pharm Res 1990: 7: 161.
5. EUGUI EM, ALMQUIST SJ, MULLER CM, ALLISON AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991: 33: 161.
6. EUGUI EM, MIRKOVICH A, ALLISON AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 191: 33: 175.
7. ALLISON AC, KOWALSKI WJ, MULLER CJ, WATERS RV, EUGUI EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993: 25(3 suppl 2): 67.
8. SOLLINGER HW, US RENAL TRANSPLANT MYCOPHENOLATE: MOFETIL STUDY GROUP. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
9. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
10. LINDHOLM A, OHLMAN S, ALBRECHTSON D, TUFVESON G, PERSSON M, PERSSON NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by three cyclosporin regimens. Transplantation 1993: 56: 307.
11. LINDHOLD A, ALBRECHTSEN D, TUFVESON G, KARLBERG I, PERSSON NH, GROTH CG. A randomized trial of cyclosporin and prednisolone versus cyclosporine, azathioprine. and prednisolone in primary cadaveric renal transplantation. Transplantation 1992: 54: 624.
12. TESI RJ, HENRY ML, ELKANNAS EA, FERGUSON RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993: 7: 345.
13. ALMOND PS, MATAS AJ, GILLINGHLAM K, DUNN DL, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993: 55: 752.